Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marina Grundman

Physician Assistant Iselin, NJ Physician Assistant

NPI 1326177528 CMS profile 10627173

400 Gill Ln, Iselin, NJ 08830

Open in the dashboard

General payments

$1,090

67 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marina Grundman of Iselin, NJ is reported in the CMS Open Payments database as having received $1,090 across 67 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $153 8
2024 General $179 10
2023 General $392 28
2022 General $239 16
2021 General $126 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marina Grundman
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Marina Grundman were reported at $153. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Marina Grundman Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $126 $132 $37–$438 $132
2022 $239 $155 $48–$522 $149
2023 $392 $167 $52–$557 $160
2024 $179 $178 $55–$600 $164
2025 $153 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $230 18 payments
  2. Novo Nordisk Inc $198 12 payments
  3. GlaxoSmithKline, LLC. $189 12 payments
  4. Lilly USA, LLC $69 5 payments
  5. Biohaven Pharmaceuticals, Inc. $66 1 payment
  6. Exact Sciences Corporation $62 3 payments
  7. CVRx, Inc. $49 2 payments
  8. Pfizer Inc. $46 3 payments
  9. Bausch Health US, LLC $37 2 payments
  10. Dexcom, Inc. $33 2 payments
  11. Other $112 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,090 67 payments
Products named General payments · program years 2021–2025
  1. FreeStyle Libre 2 $147 12 payments
  2. Wegovy $97 6 payments
  3. SHINGRIX $92 6 payments
  4. FreeStyle Libre 3 $83 6 payments
  5. Saxenda $69 4 payments
  6. AREXVY $67 4 payments
  7. NURTEC ODT $66 1 payment
  8. Cologuard Collection Kit $62 3 payments
  9. Barostim Neo System $49 2 payments
  10. MOUNJARO $40 3 payments
  11. Other $450 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

978

Median for Physician Assistant: 241

Drug cost

$32,666

Median for Physician Assistant: $4,110

Branded share of claims

16.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 12 $10,403
Eliquis Apixaban Brand 23 $9,171
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 12 $2,355
Atorvastatin Calcium Generic 144 $1,369
Amlodipine Besylate Generic 137 $960
Olmesartan-Hydrochlorothiazide Olmesartan/Hydrochlorothiazide Brand 17 $818
Levothyroxine Sodium Generic 79 $799
Rosuvastatin Calcium Generic 39 $715
Losartan Potassium Generic 102 $670
Valacyclovir Valacyclovir Hcl Brand 23 $643

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $34
$34 — —
SHINGRIX
  • GlaxoSmithKline, LLC. $17
$17 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $16
$16 — —
QULIPTA
  • AbbVie, Inc. $16
$16 — —
GARDASIL 9
  • Merck Sharp & Dohme Corporation $3
$3 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

67 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record